SpringWorks Therapeutics (SWTX) - Stock & Dividends

SpringWorks Therapeutics, Inc. is a company that focuses on acquiring, developing, and bringing to market medicines for rare diseases and cancer patients who are often overlooked. Their primary product in development is nirogacestat, an oral small molecule gamma secretase inhibitor currently in Phase III DeFi trial for the treatment of desmoid tumors.

In addition to nirogacestat, SpringWorks Therapeutics is working on mirdametinib, an oral small molecule MEK inhibitor undergoing Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for NF1-PN. They are also exploring combination therapies like mirdametinib + lifirafenib in Phase 1b/2 clinical trials for patients with advanced solid tumors.

Besides these, the company is actively developing BGB-3245, an oral selective small molecule inhibitor targeting activating BRAF mutations. SpringWorks Therapeutics has strategic collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC, while holding license agreements with Pfizer Inc. for nirogacestat and mirdametinib.

Moreover, SpringWorks Therapeutics has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a range of novel small molecule inhibitors, and with Dana-Farber Cancer Institute for another set of novel small molecule inhibitors targeting the Epidermal Growth Factor Receptor.

Founded in 2017 and based in Stamford, Connecticut, SpringWorks Therapeutics is dedicated to advancing innovative therapies for patients in need. To learn more about their work, you can visit their website at https://www.springworkstx.com.